Le Lézard
Classified in: Health, Science and technology
Subject: SVY

SymbioCellTech Announces Publication in PLOS ONE, Demonstrating 'Neo-Islets' as Significant Advance in Stem Cell Therapy for Type 1 Diabetes

SALT LAKE CITY, Sept. 20, 2019 /PRNewswire/ -- SymbioCellTech, LLC , a biotechnology company in Salt Lake City pioneering stem cell therapy for diabetes and associated auto-immune disorders and microvascular conditions, today announced the online journal PLOS ONE published interim data demonstrating ongoing safety and efficacy of "Neo-Islet" cellular therapy, a technology that co-aggregates mesenchymal stem cells with culture-expanded pancreatic islet cells to form three-dimensional cellular clusters, termed "Neo-Islets." A single dose of Neo-Islets administered into the abdominal cavity provides durable blood sugar control without the need for potentially toxic anti-rejection drugs or encapsulation devices.

Type-1 diabetes is an auto-immune disease in which the patient's own immune system attacks and destroys the islet cells of the pancreas, resulting in an inability for the body to produce insulin. The American Diabetes Association estimates that over 20% of U.S. medical expenditures can be attributed to the provision of diabetes care, and the World Health Organization estimates over 10,000 people die every day from diabetes and its associated complications. The standard cell therapy for Type 1 diabetes is islet cell transplantation into the liver, however, this approach is expensive and has serious drawbacks, including the need for potentially toxic immunosuppressive drugs, and it also suffers from a lack of available donor pancreas cells to treat the large number of patients in need of therapy.

In order to avoid the need for immunosuppressive agents, other biotechnology companies have utilized artificial encapsulation devices made from foreign material, however, scientists at SymbioCellTech have employed adult stem cells to block the immune attack on transplanted pancreatic islet cells, a process they term "natural encapsulation." By using this approach, rather than placing an artificial device in the body, the Neo-Islets do not mount a foreign body reaction that can lead to graft and therapy failure. Neo-Islets are biologically pure cellular structures that possess all functions of normal pancreatic islet cells, while permanently shielding their pancreatic islet cell component from rejection and immune-mediated destruction. 

In the PLOS ONE journal article, Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using "Neo-Islets," aggregates of adipose stem and pancreatic islet cells (INAD 012-776), SymbioCellTech scientists describe the results of implanted Neo-Islets into pet dogs that had naturally developed auto-immune Type-1 diabetes, which largely resembles human Type I diabetes. Within a few months, all treated dogs experienced a reduction in the need for exogenous insulin without the need for anti-rejection drugs or encapsulation devices. SCT previously showed the Neo-Islets continue to produce all physiological hormones that normal healthy pancreatic islets secrete (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689775/).

Based on the strength of these preclinical data, SymbioCellTech is preparing for an FDA Investigational New Drug (IND) submission to gain approval to begin testing Neo-Islet therapy in human clinical trials in patients with Type I diabetes.

In conclusion, SymbioCellTech scientists believe that Neo-Islet therapy is a durable all-biologic platform that has the potential to revolutionize the treatment of a Type I Diabetes and other auto-immune diseases. Currently, SymbioCellTech is focused on treating insulin-dependent diabetes due to the magnitude of this global medical problem.

The cited publication can be found here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218688

About SymbioCellTech:

SymbioCellTech, LLC is a privately held biotechnology company in Salt Lake City, Utah, focused on the development of stem cell therapies for the treatment of diabetes, microvascular, neurodegenerative, and auto-immune diseases. The aforementioned results are from an FDA-approved canine clinical trial testing the safety and efficacy of Neo-Islets as a functional cure for Type-1 diabetes in pet dogs. SymbioCellTech is now preparing an FDA IND submission for human clinical trials for Type-1 diabetes. For more information on SymbioCellTech, please visit www.symbiocelltech.com.   

SOURCE SymbioCellTech, LLC

These press releases may also interest you

at 02:05
RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia® this quarter and the ongoing promotion of Aemcolo® RedHill will receive an additional $50 million to fund the acquisition...

at 02:05
RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for...

at 02:00
February 25, 2020 Company provides update related to coronavirus disease 2019 (COVID-19) outbreak Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today published its Annual Report 2019, and expects to...

at 02:00
Pharmaceutics International, Inc. (Pii), a pharmaceutical contract development and manufacturing organization (CDMO), announces the expansion of its aseptic filling capacity and capabilities with the addition of a new, fully robotic filling line....

at 01:39
Elekta (EKTA-B.ST) invites analysts and investors to a meeting on April 4, in conjunction with the Annual Meeting of the European Society for Radiation Oncology (ESTRO), in Vienna, Austria. The investor meeting will be held on Saturday, April 4, at...

at 01:35
Regulatory News: Lysogene (Paris:LYS) (FR0013233475 ? LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

News published on 20 september 2019 at 22:13 and distributed by: